Radiotherapy in the treatment of postoperative chylothorax by unknown
RESEARCH ARTICLE Open Access
Radiotherapy in the treatment of postoperative
chylothorax
Zsolt Sziklavari1, Michael Allgäuer2, Georg Hübner2, Reiner Neu3, Michael Ried3, Christian Grosser1, Tamas Szöke1,
Rudolf Schemm1 and Hans-Stefan Hofmann1,3*
Abstract
Background: Chylothorax is characterized by the presence of chyle in the pleural cavity. The healing rate of non-
operative treatment varies enormously; the maximum success rate in series is 70%. We investigate the efficacy and
outcomes of radiotherapy for postoperative chylothorax.
Methods: Chylothorax was identified based on the quantity and quality of the drainage fluid. Radiation was
indicated if the daily chyle flow exceeded 450 ml after complete cessation of oral intake. Radiotherapy consisted of
opposed isocentric portals to the mediastinum using 15 MV photon beams from a linear accelerator, a single dose
of 1–1.5 Gy, and a maximum of five fractions per week. The radiation target area was the anatomical region
between TH3 and TH10 depending on the localization of the resected lobe. The mean doses of the ionizing energy
was 8.5 Gy ± 3.5 Gy.
Results: The median start date of the radiation was the fourth day after chylothorax diagnosis. The patients’
mediastinum was radiated an average of six times. Radiotherapy, in combination with dietary restrictions, was
successful in all patients. The median time between the end of the radiation and the removal of the chest tube
was one day. One patient underwent wound healing by secondary intention. The median time between the end of
radiation and discharge was three days, and the overall hospital stay between the chylothorax diagnosis and
discharge was 18 days (range: 11–30 days). After a follow-up of six months, no patient experienced chylothorax
recurrence.
Conclusions: Our results suggest that radiotherapy in combination with dietary restriction in the treatment of
postoperative chylothorax is very safe, rapid and successful. This novel interventional procedure can obviate repeat
major thoracic surgery and shorten hospital stays and could be the first choice in the treatment of
postthoracotomy chylothorax.
Keywords: Chylothorax, Radiotherapy, Postoperative complication
Background
Chylothorax is characterized by the presence of chyle,
which is rich in triglycerides and chylomicrons, in the
pleural cavity. There are four typical causes of chylothorax:
tumor, trauma, idiopathic and miscellaneous. Chylothorax
also complicates up to 3% (0,26 – 3%) of intrathoracic
procedures (not including esophagus surgery), especially
in patients undergoing radical mediastinal lymph node
dissection. Thoracic surgery involving esophageal surgery
has a maximum chylothorax incidence of 4% [1]. In cases
of chronification, malnutrition and immunologic compli-
cations can occur, and a mortality rate of up to 50% has
been reported [2]. Currently, the morbidity and mortality
associated with chylothorax have improved due to the im-
plementation of more aggressive management strategies.
Conservative treatment of chylothorax includes chest
tube drainage and enteral/parenteral dietary management,
which is based on the restriction of long chain fatty acids
and triglycerides. The daily output from the chest tube is
most likely the most important indicator of the patient’s
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chance of success with conservative treatment. The healing
rate of non-operative treatment varies enormously.
If drainage remains >1000 ml/day, surgical intervention
has been shown to reverse the adverse effects of chyle [3].
This management strategy decreased the mortality rates
for chylothorax [4]. However, especially in cases of postop-
erative chylothorax, repeated surgical procedures were
necessary due to a complicated clinical course. Repeat op-
erations are necessary in up to 72% of cases and include
video-assisted thoracic surgery (VATS) and repeat thora-
cotomy for pleurectomy, talc pleurodesis or ligation of the
thoracic duct [3].
Because of the time-consuming conservative treatment
and the limited results with interventional and surgical
treatment we sought to develop an alternative therapy
for postoperative chylothorax. Due to the good out-
comes in the treatment of inguinal lymph fistulas with
radiotherapy [5] and some well documented case reports
describing the successful management of malignant
chylothorax with radiotherapy [6,7], we investigated the
efficiency and outcome of radiotherapy for postoperative
chylothorax.
Methods
In this retrospective study, we investigated seven pa-
tients with postoperative chylothorax who were treated
at our department between April, 2010 and October,
2011. Chylothorax was identified based on the quantity
and milky aspect of the drainage fluid, and the diagnosis
was confirmed based on the documentation of elevated
triglyceride levels (>110 mg/dl) in the pleural fluid.
The mean age of the patients (male=4, female=3) was 59
years (range: 27 to 74 years). The cause of chylothorax in
all seven cases was thoracotomy. In four of the cases,
chylothorax developed following antero-lateral thoracot-
omy for a lobectomy (n=4), and in 2 cases, chylothorax
developed following a wedge resection procedure (n=2);
all six of these cases also involved radical lymphadenec-
tomy. One patient underwent a sternotomy for thymec-
tomy without lymph node dissection. A left-sided
chylothorax was observed in two patients, and a right-
sided chylothorax was observed in five patients. The pa-
tient demographics and lung pathologies are summarized
in Table 1.
All patients had chest tubes placed after their initial
operation. Patients 1, 4 and 7 with highly chyle flow had
complete cessation of oral intake (parenteral alimenta-
tion), whereas the other four patients were restricted to
a fat free diet (exception: medium-chain triglycerides-
MCT). Moderate chest tube suction at 20 cm H2O was
applied. Radiation was indicated if the daily chyle flow
exceeded 450 ml after complete oral intake cessation
and total parenteral nutrition or fat free diet. A lymph-
angiography for the identification of the leakage was not
performed. The radiotherapy was administered with the
written informed consent of the patients. Radiotherapy
consisted of opposed isocentric portals to the mediasti-
num using 15 MV photon beams from a linear acceler-
ator (Synergy, Elekta Stockhom, Sweden), a single dose
of 1–1.5 Gy, and a maximum of five fractions per week.
The target radiation area was the posterior mediastinum
between TH3 and TH10 depending on the localization
of the resected lobe. The mean doses of the ionizing en-
ergy was 8.5 Gy ± 3.5 Gy. Monitoring of the serum elec-
trolytes, lymphocyte count, albumin, total protein and
the patients’ weight was performed.
The medical records were retrospectively reviewed and
the following information was collected: patient age, pa-
tient sex, clinical course, side of thoracotomy, etiology,
radiotherapy course, mean quantity of daily chyle, dur-
ation of drainage, length of hospital stay and outcome.
All patients were followed up. The mean follow-up
period was 6 months (3–16 months). Because of the
skewed distributions, we mostly used the median as a lo-
cation parameter in descriptive statistics. The outcomes
are summarized in Table 2.
Results
At our institution, postoperative chylothorax occurred in
2.8% of the cases involving thoracic surgery with radical
systematic lymphadenectomy. The manifestation of the
chylothorax occurred between the 1st and 14th postoper-
ative day (median, 2nd day). The mean pre-radiation
daily chyle flow was 800 ml/day (range: 450–1700 ml/
day) with a mean concentration of triglycerides of 224
mg/dl (range: 121–1185 mg/dl).
The median start date of the radiation was on the
fourth day (range second-21st day) after diagnosis of the
chylothorax. Treatment of the first patient was delayed
until the 21st postoperative day because the radio-
oncologists were hesitant due to the uncertain outcomes
of this novel treatment modality. Radiotherapy, including
enteral or parenteral, no-fat diet was successful in all pa-
tients. The mediastinum of the patients was radiated a
mean of six times (range 3–10 times). During radiother-
apy and diet, the mean concentration of triglycerides de-
creased to 157 mg/dl (range 61–642 ml/day). After
radiation, the mean chyle flow was 90 ml/dl (range: 0–
150 ml/day) (Figure 1). The median time between the
end of the radiation therapy and the removal of the
chest tube was one day (range: 1–8 days).
The enteral or parenteral no-fat diet was continued
until the end of radiotherapy. One day later, the lymph-
atic system was activated with a fatty meal. If the drain-
age fluid remained non-chylous and did not increase,
the chest tube was removed.
The majority of the patients had no major complica-
tions after radiation. One patient underwent wound
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Table 1 Patient demographics
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Age 74 70 57 59 47 38 62
Sex Male Male Female Male Male Female Male
Karnofsky-Index <70% Yes No Yes No No No Yes
Histology NSCLC Stage IA NSCLC Stage II A NSCLC Stage III A Pseudotumor Metastasis Thymoma Metastasis
Neoadjuvant Therapy No No Yes No Yes No Yes
Localisation Right upper lobe Left lower lobe Left lower lobe Left lower lobe Right midle, lower lobe Mediastinum Right upper lobe
Primary Operation Lobectomy Lobectomy Lobectomy Lobectomy Wedge- resection Thymectomy Wedge- resection
Lympadenectomy Yes Yes Yes Yes Yes No Yes
Diagnosis, postoperative day 14th 6th 2nd 3rd 1st 2nd 2nd
Cholesterol level mg/dl of drainage fluid at Diagnosis° 35 42 45 48 190 65 37
Triglyceride level of drainage fluid mg/dl at Diagnosis° 121 491 371 123 186 1185 224














healing by secondary intention, and another patient de-
veloped urosepsis that was not related to the treatment.
The median time between the end of the radiation ther-
apy and discharge was three days (range: 2–13 days),
and the overall hospital stay between the diagnosis of
chylothorax and discharge was 18 days (range: 11–30
days). After a mean follow-up of six months, no patient
experienced chylothorax recurrence.
Discussion
The present study is the first to show, in a significant num-
ber of patients, that postoperative chylothorax can be effect-
ively healed with a combination of radiotherapy and diet.
Chylothorax is a rare condition that results from thor-
acic duct injury and usually occurs on the right side.
The most common causes of chylothorax are malig-
nancy and trauma [8].
Currently, thoracic surgery has replaced physical injury
as the leading cause of trauma; esophageal surgery ac-
counts for most of these cases with a maximum incidence
of 4% [1]. The incidence of postoperative chylothorax fol-
lowing thoracic surgery without esophageal surgery varies
between 0,26% and 3% (Table 3).
Mediastinal lymphadenectomy seems to be responsible
for the higher incidence of postoperative chylothorax after
lung cancer resection [9-12,15]. Patients who underwent
only sampling of the mediastinal lymph nodes did not de-
velop chylothorax [9,10]. Bollen et al. [9] and Izbicki et al.
[10] reported a postoperative chylothorax rate at the be-
ginning of systemic radical mediastinal lymph node dissec-
tion of 3% (n=2/65) and 1.2% (n=1/84), respectively. In a
larger group of patients (n=1110) undergoing pulmonary
resection and systematic mediastinal lymph node dissec-
tion for lung cancer, Shimizu et al. reported 27 patients
(2.4%) with postoperative chylothorax [12]. Zabeck et al.
reported, that in 25 of their 26 postoperative chylothorax
cases, complete mediastinal lymph node dissection was
performed [15]. In six of our seven cases, complete medi-
astinal lymph node dissection was performed. At our insti-
tution, postoperative chylothorax occurred in 2.8% of the
cases involving thoracic surgery with radical systematic
lymphadenectomy. The role of pneumonectomy with me-
diastinal lymph node dissection in the development of
chylothorax is unclear. Le Pimpec-Barthes et al. encoun-
tered a significantly higher incidence of chylothorax when
pulmonary resection consisted of a pneumectomy com-
pared with (bi)lobectomy (5/8 vs. 1/18) [11]. In the pa-
tients in the studies conducted by Cerfolio et al. and
Shimizu et al., pneumonectomy did not increase the inci-
dence of chylothorax [3,12].
Postoperative chylothorax during the initial operation
can be prevented by performing careful dissection and
liberal clipping of lymphatic vessels, particularly in the
posterior mediastinum. Guo et al. reported that thoracic
duct ligation during VATS-esophagectomy for cancer is
an effective and safe method for preventing chylothorax
[16]. However, there is no consensus or formal guide-
lines regarding the safe preparation of lymph nodes for
lung cancer to prevent postoperative chylothorax.
In patients with postoperative or post-traumatic chylo-
thorax, some authors considered the anatomical location
of the thoracic duct injury. Ruan et al. recommends
lymphangiography in patients with intractable spontan-
eous chylothorax [17]. They found that this diagnostic
procedure may facilitate the occlusion of the leakage site
and the prediction of the occurrence of adverse events
due to thoracic duct ligation. We think that radiation
therapy for secondary chylothorax does not require any
type of leakage detection.
Current treatment modalities for postoperative chylo-
thorax include conservative, interventional and surgical
therapies.
The principles of conservative chylothorax treatment in-
clude efficient drainage, inflation of the lung to decrease
Table 2 Therapy and outcomes
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7
Begin of Radiation after Diagnosis (d) 9th 4th 4th 2nd 11th 21st 3rd
Number of Radiations (n) 6 8 8 5 3 3 10
Radiation-Energy (Gy) 6 12 8 5 9 9 10
Max..Flow before Radiation (ml/d) 1100 450 850 800 710 450 1700
Max. Flow after Radiation (ml/d) 0 150 90 90 200 220 0
Day of the chest tube removal after Radiation 1st 1st 1st 2nd 8th 7th 1st
Length of hospital after Diagnosis (d) 23 18 15 11 21 30 16
Length of hospital after Radiation (d) 5 3 2 3 13 7 2
Cholesterol after Radiation, mg/dl 35 n.a. n.a. 67 n.a. 54 50
Triglyceride after Radiation mg/dl 121 n.a. n.a 40 n.a 126 74
Re-Chylothorax No No No No No No No
Complications - - - - Urosepsis - -
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the dead space in the thoracic cavity and to promote adhe-
sion of the lung or pleura to the thoracic duct injury, and
cessation of flow (diet/parenteral nutrition) through the
thoracic duct to accelerate fistula closure. Conservative
treatment must be initiated at the time of diagnosis and
results in resolution of the chylothorax in 23% to 70% of
cases (Table 4, if n >1).
Interventional/surgical management should be adopted
if conservative management fails. The interventional ther-
apies include VATS for pleurodesis, percutaneous lymph-
angiography and radiotherapy. Schoellnast et al. reported
a 50% success rate after needle disruption of the cisterna
chyli with subsequent resolution of the chylothorax [20].
Cope found that two thirds of patients presenting with
life-threatening chylothorax can be safely treated with per-
cutaneous transabdominal thoracic duct blockage [19].
Promotion of adhesions of the lung and pleura to the thor-
acic duct injury by pleurodesis may play an important role
in the treatment of chylothorax. Talc pleurodesis is
successful in 73% to 83% of all cases [13,14]. The injection
of OK-432, which is a heat- and penicillin-treated lyophi-
lized preparation of the Su strain of Streptococcus
pyogenes, into the thoracic cavity is effective and safe in
managing postoperative chylothorax and exhibited a
success rate of 87% [12]. Other therapeutic options such
as the intrapleural instillation of octreotide/somatostatin,
streptokinase or fibrin glue therapy were only published as
case reports [18,21,22].
Surgical treatment generally involves ligation of the
thoracic duct. Thoracic surgeons often recommend reope-
ration to ligate the thoracic duct when conservative ther-
apy fails [3,12,15]. Surgical intervention offers better
results than conservative management when the daily
chyle flow exceeds 500 ml/day in adults [12]. Zabeck et al.
found that in postoperative chylothorax with a high flow
of >900 ml/day, repeat surgery should be performed as
soon as possible because conservative management is
likely to be unsuccessful [15].
Radiotherapy of inguinal lymph fistulas is a well-
established, effective and well-tolerated treatment option.
Because fistulas completely close after radiotherapy, this
procedure is a good alternative to other conservative treat-
ment modalities [5]. The motivations for our study were
some well documented case reports that described the
successful management of malignant chylothorax with
radiotherapy [6,7].
Analogously, there are several potential advantages of
using radiation to treat chylothorax. The early use of ra-
diation therapy may rapidly arrest the progression of








Flow before Radiation Flow while Radiation Flow after Radiation
m
l/d
Figure 1 Mean flow of the drainage fluid in ml/die before, while and after radiation.
Table 3 Incidence of secondary chylothorax following thoracic surgery
Author (year) [Reference] Kind of ymphnodedissection Incidence of postoperative chylothorax (%)
Bollen et al. 1993 [9] Mediastinal lymph node dissection 3
Izbicki et al. 1994 [10] Radical systematic lymphadenectomy 1.2
Cerfolio et al. 1996 [3] n.a. 0.26
Le Pimpec-Barthes et al. 2002 [11] Mediastinal lymph node dissection 0.65
Shimizu et al. 2002 [12] Mediastinal lymph node dissection 2.4
Paul et al. 2009 [13] Three-field dissection 2.6
Akin et al. 2011 [14] Mediastinal lymph node dissection 1.9
Own results Radical systematic lymphadenectomy 2.4
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procedures. Up to 11% of the patients with postoperative
chylothorax underwent repeat surgical procedures due
to complications, and 9% experienced recurrence of
their chylothorax [15]. Shimizu et al. reported that com-
plications following VATS pleurodesis and repeat thora-
cotomy occurred in 15% of cases [12].
Accordingly, the median length of hospital stay was
shorter in our group (median, 18 [range 11–30] days)
compared with the group that underwent (redo) oper-
ation in the studies of Kashiowanoha (19 [range 12–36]
days) and Heidelberg (26 [range 15–205] days), respect-
ively [12,15].
Table 4 Treatment modalities and outcomes for secondary chylothorax
Treatment Author (year) [Reference] n= Success rate (%)
Conservative
Diet/parenteral nutrition Cerfolio et al. 1996 [3] 47 28
Somatostatin-Infusion Rimensberger et al. 1998 [18] 1 100
Medium Chain Triglycerides Diet Le Pimpec-Barthes et al. 2002 [11] 26 50
Parenteral nutrition Shimizu et al. 2002 [12] 26 23
Diet/parenteral nutrition Chalret du Rieu et al. 2011 [2] n.a. 70
Diet/parenteral nutrition Zabeck et al. 2011 [15] 37 32
Interventional
Percutaneous Embolization Cope 2004 [19] 60 65
Pedal Lymphangiography Le Pimpec-Barthes et al. 2002 [11] 7 57
Pleurodesis (OK-432) Shimizu et al. 2002 [12] 15 87
Pleurodesis (talc) Paul et al. 2009 [13] 6 83
Pleurodesis (talc) Akin et al. 2011 [14] 26 73
Direct lymphangiography Schoellnast et al. 2011 [20] 2 50
Surgery
Duct ligation Cerfolio et al.1996 [3] 32 94
Duct ligation Shimizu et al. 2002 [12] 5 100
Duct ligation/Loc. Suture Le Pimpec-Barthes et al. 2002 [11] 5 83
Duct ligation Paul et al. 2009 [13] 22 95
Duct ligation Akin et al. 2011 [14] 7 100
Chylothorax 
Nil by mounth diet
Total parenteral 
nurition 24 h long
Chylothorax < 400 ml /day Chylothorax > 400 ml/day
Fat free diet1





If daily flow < 150 ml 
faty meal challenge
If daily flow > 150 ml 
continue radiation up 
to 12 Gy
If daily flow < 150 ml 
Remove Drainage
1exception: medium-chain triglycerides-MCT
Figure 2 Therapy recommendation for postoperative chylothorax.
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The major disadvantage to using radiation therapy for
chylothorax is the possibility for acute and long-term side
effects that vary by treatment site. On the other hand, no
patient developed in our study radiation side effect (e.g.
pneumonitis) after the low-dose radiotherapy. While mod-
erate/severe radiation-induced side effects are rare, the po-
tential for secondary malignancy and growth restriction
should be considered before administering high-dose radi-
ation therapy especially to children.
The great advantages of radiation therapy with a max-
imum of 12 Gy include the low incidence of acute and
long-term side effects. After a mean follow-up of 6
months, no recurrent chylothorax or other complications
were observed in any of the seven patients. All of these
patients reported a very good quality of life in an out-
patient interview.
Future studies should investigate the required minimum
energy that is required to eliminate the chyle leakage.
Study limitation
The limitation of our study was the small number of
patients.
Conclusion
Our results suggest that radiotherapy in combination with
diet in the treatment of postoperative chylothorax is very
safe, rapid and successful. Our therapy recommendation is
summarized in Figure 2. This interventional procedure
can obviate repeat major thoracic surgery and shorten
hospital stays and could be the first choice in the therapy
of postthoracotomy chylothorax.
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